While Philips reported Q1 sales slightly above consensus, the performance weakness was evident. With management acknowledging risk of further business challenges, the prospect of near-term normalisation seems difficult and, hence, markets have been spooked again. A tricky product recall/remediation action is an added concern. The only saving grace for now is a ‘still growing’ order-book. While multi-year share price lows and order-book-driven business visibility are good reasons to buy the stock ....
25 Apr 2022
Recovery delayed – once again!
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Recovery delayed – once again!
While Philips reported Q1 sales slightly above consensus, the performance weakness was evident. With management acknowledging risk of further business challenges, the prospect of near-term normalisation seems difficult and, hence, markets have been spooked again. A tricky product recall/remediation action is an added concern. The only saving grace for now is a ‘still growing’ order-book. While multi-year share price lows and order-book-driven business visibility are good reasons to buy the stock ....